Navigation Links
Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
Date:2/27/2008

TOKYO, Feb. 27 /PRNewswire/ -- Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States), its wholly owned U.S. subsidiary, received on February 25, 2008 (local time) a Not approvable letter from the U.S. Food and Drug Administration (FDA) for istradefylline (KW-6002), its investigational drug for the treatment of Parkinson's disease.

In the not approvable letter FDA expressed concern if the efficacy findings support clinical utility of istradefylline (KW-6002). FDA requested an overall summary of nonclinical mineralization findings. Additionally, FDA asked for clinical pharmacology follow-up information as a Phase 4 commitment.

After closely examining the FDA's response, Kyowa Hakko will work closely with FDA and conduct a comprehensive discussion to determine a path forward for istradefylline (KW-6002).

Istradefylline (KW-6002) has a novel mechanism of action that antagonizes the adenosine A2A receptor. It has been under FDA review as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.

Kyowa Hakko is a biotechnology-based company focused on two businesses: pharmaceutical operations engaged in the research and development, manufacturing, and marketing of prescription drugs; and bio-chemical operations that handle a variety of products such as amino acids, nucleic acids, and nutritional supplements/healthcare products. Its pharmaceutical business places emphasis on research and development in the fields of oncology, allergy, and the central nervous system. In Japan, Kyowa Hakko is marketing medications for a wide range of diseases, including allergy, hypertension, angina pectoris, and cancer. With the aim of penetrating the global market, Kyowa Hakko has overseas development bases in the U.S. (Kyowa Pharmaceutical, Inc. and BioWa, Inc.) an
'/>"/>

SOURCE Kyowa Hakko Kogyo Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Two champions of science, technology, engineering, and mathematics ... competition for middle and high school students designed to ... The competition presents students with real-world problems experienced by ... and Sciences is a program administered by the ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... ... Earned Value Management can improve control over clinical development costs, payments, and accruals and ... , ... June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical trial ...
... STAAR Surgical Company (Nasdaq: STAA ), a ... products, today announced that the FDA has granted 510(k) ... the Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone ... a new era of insertion devices for the company ...
... June 11 New data from Phase 3 ... (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* ... provide coverage against the 13 most prevalent serotypes associated with ... children younger than five worldwide. , , ...
Cached Biology Technology:ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6
(Date:7/10/2014)... 10, 2014) Consuming a whole fresh avocado with ... enhanced provitamin A carotenoid (alpha- and beta-carotene) absorption and ... vitamin A, according to new research (1) published ... , Vitamin A is involved in reproductive health ... and vision; and has antioxidant properties. Provitamin A carotenoids, ...
(Date:7/9/2014)... diseases can occur simultaneously in distinct sites in ... effective for one disorder may exacerbate the other. ... which alleviates joint disease but can worsen periodontal ... of The American Journal of Pathology ... anti-arthritic drugs, specifically DTrp8-ɣMSH (DTrp), that acts via ...
(Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
Breaking Biology News(10 mins):New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3
... Rebekah E. Gee MD MPH FACOG, Assistant Professor, LSU ... and Medicine, has been chosen to receive a Recognition ... Leadership Award from the Association of Maternal & Child ... vision, and contributions to the health of women, children, ...
... The University of Michigan,s first human embryonic stem cell line ... registry, making the cells available for federally-funded research. It is ... University of Michigan to be placed on the registry. ... derived in October 2010 from a cluster of about 30 ...
... cues from their rivals the honeybees to learn where the ... Mary, University of London. Writing in the journal ... Biological and Chemical Sciences explain how they trained a colony ... by a different species, the honeybee ( Apis mellifera ), ...
Cached Biology News:LSUHSC's Gee honored for improving health of women, children and families 2U-M human embryonic stem cell line placed on national registry 2U-M human embryonic stem cell line placed on national registry 3Bumblebees get by with a little help from their honeybee rivals 2
...
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
Biology Products: